Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication XDEMVY is indicated for the treatment of Demodex blepharitis. XDEMVY is an ectoparasiticide (anti-parasitic) indicated for the treatment of Demodex blepharitis. ( 1 ) FDA label
Also known as TP-03, S-Misoxam
Lotilaner · 1 trial · 1 indication
To demonstrate the efficacy of 0.25% Lotilaner Ophthalmic Solution to eliminate collarettes and eradicate mite in Demodex blepharitis
To demonstrate the efficacy of 0.25% Lotilaner Ophthalmic Solution to eliminate collarettes and eradicate mite in Demodex blepharitis
To demonstrate the safety of 0.25% TP-03 in Demodex blepharitis
| Arm | Type | Description |
|---|---|---|
| Lotilaner Ophthalmic Solution (TP-03) | EXPERIMENTAL | Lotilaner Ophthalmic Solution (TP-03) |
| Vehicle Control | PLACEBO_COMPARATOR | Vehicle Control |
| Name | Type | Description |
|---|---|---|
| Lotilaner | DRUG | Lotilaner Ophthalmic Solution |
| Vehicle Control | DRUG | Vehicle of TP-03 ophthalmic solution |
Inclusion Criteria: 1. Male or female, aged ≥ 18 years of age. 2. Be willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol. 3. Has blepharitis 4. Stated willingness to comply with all study procedures and availability for the duration of th...
Top 1 of 2 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 1 | PHASE4 | GLK-321 |